Introduction Elderly patients are the most affected and vulnerable to COVID-19 and effective
therapeutic interventions are urgently required. We clarified the safety and efficacy of …

Objective: To evaluate the efficacy of Paxlovid in treating Chinese elder patients infected
with SARS-CoV-2 omicron variants. Methods: We performed a non-randomized, controlled …

This study aimed to clarify the beneficial effect and the clinical application value of Paxlovid
in the treatment of coronavirus disease‐19 (COVID‐19) through a systematic review …

Summary Background Nirmatrelvir plus ritonavir (Paxlovid) reduced the risk of
hospitalization or death by 89% in high-risk, ambulatory adults with COVID-19. We aimed at …

Background Paxlovid is an oral antiviral drug that received emergency use authorization in
South Korea for the treatment of patients with mild-to-moderate coronavirus disease 2019 …

Background Paxlovid was granted an Emergency Use Authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …

To the Editor, Nirmatrelvir/ritonavir (Paxlovid) is an oral antiviral drug that has been shown to
reduce the risk of hospitalization, severe COVID‐19, and mortality among mild‐to‐moderate …

Since the outbreak of COVID-19, caused by the SARS-CoV-2, in December 2019, the
ongoing pandemic has posed 5 318 216 deaths worldwide. 1 Vaccines, traditional Chinese …

Coronavirus infection is a pandemic threat and the most dangerous disease of the 21 st
century. Despite the rigorous exertion of world-class researchers, there is no perfect cure for …

Background: Studies on the Omicron variant infection have generally been restricted to
descriptions of its initial clinical and epidemiological characteristics. We investigated the …